Fate Therapeutics, Inc. (FATE)

Market Cap	207.97M
Revenue (ttm)	119.25M
Net Income (ttm)	-211.56M
Shares Out	98.56M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,672,661
Open	2.22
Previous Close	2.19
Day's Range	2.10 - 2.23
52-Week Range	2.10 - 23.96
Beta	1.47
Analysts	Hold
Price Target	6.90 (+227.01%)
Earnings Date	Nov 2, 2023

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the dev...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2013
• Employees: 551
• Stock Exchange: NASDAQ
• Ticker Symbol: FATE

Financial Performance

In 2022, FATE's revenue was $96.30 million, an increase of 72.44% compared to the previous year's $55.85 million. Losses were -$281.72 million, 32.8% more than in 2021.

Analyst Forecast

According to 19 analysts, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $6.9, which is an increase of 227.01% from the latest price.

Price Target

$6.9

(227.01% upside)

Analyst Consensus: Hold